Popular
PTGX · Medicine & biotech · U.S.

Protagonist Therapeutics

Created the psoriasis pill Icotyde and a shot for a rare blood cancer.

Company Health

73
/100
Healthy
A quick check of the business from its yearly reports (2022–2025). It doesn’t say whether the stock is a good buy.
Does it make money?
0 of 25 · Poor
It lost money last year: $283 of every $100 in sales.
Is it growing?
23 of 25 · Good
Sales grew about 20% a year over the last 3 years.
Can it handle what it owes?
25 of 25 · Good
It holds more cash than everything it owes.
Does it bring in spare cash?
25 of 25 · Good
After paying for buildings and equipment, $122 of every $100 in sales was left as spare cash.

Who owns it

1 of 23 own it · 1 bought more lately
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Himalaya Capital, Greenlight, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Protagonist Therapeutics’ yearly reports. Tap a year to see its figures.

Sales and profit

Sales grew from $28.6 million in 2020 to $46.0 million in 2025, and it made a profit in 1 of the 6 years.
2025
Sales
$46.0 million
Loss
$130 million

Spare cash each year

It had cash to spare in 2 of the 6 years, including $56.1 million in 2025.
2025
Spare cash
$56.1 million
Spare cash is the cash its business brought in, minus what it spent on buildings and equipment.

What it owns and what it owes

At the end of 2025 it owned $668 million, including $128 million in cash, and owed $53.5 million.

Key facts

From its yearly report for 2025.
Sales
$46.0 million
Loss
$130 million
Spare cash
$56.1 million
Cash in the bank
$128 million
Everything it owes
$53.5 million
Year ends
December
Money shown in
U.S. dollars
Latest yearly report
10-K, filed Feb 25, 2026
Figures from Protagonist Therapeutics’ yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy